Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Ovarian Neoplasms 16Neoplasms 6Breast Neoplasms 6Prostatic Neoplasms 4Fallopian Tube Neoplasms 4Pancreatic Neoplasms 3Triple Negative Breast Neoplasms 2Prostatic Neoplasms, Castration-Resistant 2Neoplasm Metastasis 2Head and Neck Neoplasms 2Esophageal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Uveal Melanoma 1Uterine Cervical Neoplasms 1Urologic Neoplasms 1Stomach Neoplasms 1Prostate Adenocarcinoma 1Pancreatic Adenocarcinoma 1Osteosarcoma 1Oligodendroglioma 1Neuroblastoma 1Metastatic Castration-sensitive Prostate Cancer 1Mesothelioma 1Melanoma 1Lung Neoplasms 1Glioma 1Glioblastoma 1Endometrial Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1

Interventions

niraparib 1Prednisone 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Metastatic Castration-sensitive Prostate Cancer × niraparib × Clear all
NCT04497844 2026-05-11

AMPLITUDE

Janssen Research & Development, LLC

Phase 3 Active not recruiting
696 enrolled 15 charts 1 FDA
Genitourinary

Metastatic Castration-sensitive Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡